HPV vaccination: The most pragmatic cervical cancer primary prevention strategy

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

(2014) K Kavanagh et al.   BRITISH JOURNAL OF CANCER

The Australian Experience With the Human Papillomavirus Vaccine

(2014) Suzanne M. Garland   CLINICAL THERAPEUTICS

Early Impact of Human Papillomavirus Vaccination on Cervical Neoplasia--Nationwide Follow-up of Young Danish Women

(2014) B. Baldur-Felskov et al.   JNCI-Journal of the National Cancer Institute

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination

(2014) Barbara Romanowski et al.   Human Vaccines & Immunotherapeutics

Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study

(2014) Mark Jit et al.   Lancet Global Health

Integration of comprehensive women’s health programmes into health systems: cervical cancer prevention, care and control in Rwanda

(2013) Agnes Binagwaho et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

(2013) M. Safaeian et al.   Cancer Prevention Research

Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries

(2013) Iacopo Baussano et al.   INTERNATIONAL JOURNAL OF CANCER

Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women

(2013) Simon R. M. Dobson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review

(2013) Michaela Fesenfeld et al.   VACCINE

Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months

(2013) Eduardo Lazcano-Ponce et al.   VACCINE

Updating the Natural History of Human Papillomavirus and Anogenital Cancers

(2012) Anna-Barbara Moscicki et al.   VACCINE

A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines

(2012) John T. Schiller et al.   VACCINE

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

(2011) Barbara Romanowski et al.   Human vaccines & immunotherapeutics

Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine

(2011) Aimée R. Kreimer et al.   JNCI-Journal of the National Cancer Institute

Cost-Effectiveness Analysis of a Quadrivalent Human Papilloma Virus Vaccine in Mexico

(2009) Luz Myriam Reynales-Shigematsu et al.   ARCHIVES OF MEDICAL RESEARCH

Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status

(2008) Ritu Salani et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India

(2008) M Diaz et al.   BRITISH JOURNAL OF CANCER

Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study

(2008) Margaret RE McCredie et al.   LANCET ONCOLOGY